A review discussing BPC 157 as a potential treatment for COVID-19 echoes similar issues with available data surrounding BPC 157, but does note that BPC 157 has been proven to be efficacious and safe in clinical trials evaluating its use for inflammatory bowel disease (mild to moderate ulcerative colitis)
You will find that oral tablets and injections (subcutaneous and intramuscular) are the most commonly used formats
This 2018 review by Loren Pickart (who originally discovered GHK-Cu in the 1970s) and Anna Margolina brings together decades of research and adds groundbreaking gene expression analysis showing that GHK-Cu affects nearly a third of all human genes
Observed outcomes include specific cellular and molecular endpoints such as: Enhanced fibroblast migration capacity Increased collagen and elastin deposition Modulation of pro-inflammatory and antioxidant mediators Altered transcriptional profiles related to tissue homeostasis, repair signaling, and stress response All reported observations derive exclusively from preclinical laboratory and animal studies and remain model-specific
Who It's For: People experiencing symptoms of brain fog, chronic fatigue, or seeking to enhance cognitive function often turn to NAD therapy for its rejuvenating effects
